Grifols posts positive Phase III data for BT524 in acquired fibrinogen deficiency

14 February 2024

Spanish plasma-derived products specialist Grifols (MCE: GRF) saw its shares close up around 2% at 10.64 euros today, after it announced positive, top-line Phase III data for BT524, a fibrinogen concentrate being studied to treat patients with acquired fibrinogen deficiency, a bleeding disorder.

BT524 is being developed by Biotest, a German rival that Grifols acquired for around $1.9 billion in 2021, having had an earlier bid for the company rejected by the US Federal Trade Commission. The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as its pipeline and sales presence, the company said.

This data follows Phase I/III studies in patients with congenital forms of the disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK